Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
Affinity and avidity in antibody-based tumor targetingStephen I Rudnick, Gregory P AdamsCancer Research|March 17, 2011
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumorsStephen I Rudnick, Jianlong Lou, Calvin C Shaller, et al.Molecular Cancer Therapeutics|November 18, 2011
Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicityYu Cao, James D Marks, Qian Huang, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|April 11, 2013
Interferon-γ-induced necrosis: an antitumor biotherapeutic perspectiveSiddharth Balachandran, Gregory P AdamsProceedings of the National Academy of Sciences of the United States of America|September 12, 2008
Effects of local mRNA structure on posttranscriptional gene silencingStephen I Rudnick, Jyothishmathi Swaminathan, Marina Sumaroka, et al.Expert Opinion on Biological Therapy|March 5, 2004
Radioimmunotherapy with engineered antibodiesMaria G Russeva, Gregory P AdamsNature Biotechnology|September 10, 2005
Monoclonal antibody therapy of cancerGregory P Adams, Louis M WeinerCancer Journal (Sudbury, Mass.)|June 10, 2008
Antibody engineering principles and applicationsLiNa Loo, Matthew K Robinson, Gregory P AdamsMolecular Pharmacology|October 12, 2004
Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymesDavid R Bauman, Stephen I Rudnick, Lawrence M Szewczuk, et al.Annual Review of Medicine|January 15, 2003
Monoclonal antibody therapy for cancerMargaret von Mehren, Gregory P Adams, Louis M WeinerPageof 5